Adalimumab, also known as Humira, is an anti-tumour necrosis factor (TNF) drug that blocks the action of TNF, reducing inflammation. TNF is a protein over-produced in people with rheumatoid arthritis and other inflammatory diseases which causes inflammation and damage to the joints. Unchecked inflammation of rheumatoid arthritis leads to destruction of the joints. Inflammation in Crohn's disease can lead to strictures of the intestine. Adalimumab is also used to treat active ulcerative colitis. It is injected under the skin.